vs

Side-by-side financial comparison of INTERGROUP CORP (INTG) and STANDARD BIOTOOLS INC. (LAB). Click either name above to swap in a different company.

STANDARD BIOTOOLS INC. is the larger business by last-quarter revenue ($19.6M vs $17.3M, roughly 1.1× INTERGROUP CORP). INTERGROUP CORP runs the higher net margin — 8.8% vs -177.4%, a 186.2% gap on every dollar of revenue. On growth, INTERGROUP CORP posted the faster year-over-year revenue change (19.8% vs -11.5%). INTERGROUP CORP produced more free cash flow last quarter ($-481.0K vs $-23.1M). Over the past eight quarters, INTERGROUP CORP's revenue compounded faster (7.8% CAGR vs -12.2%).

Intergroup Corp is a diversified holding firm operating two core segments: real estate and hotel operations. It owns, manages and leases commercial and residential properties across the U.S., and runs limited-service hotels for leisure and business travelers.

Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs), and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.

INTG vs LAB — Head-to-Head

Bigger by revenue
LAB
LAB
1.1× larger
LAB
$19.6M
$17.3M
INTG
Growing faster (revenue YoY)
INTG
INTG
+31.3% gap
INTG
19.8%
-11.5%
LAB
Higher net margin
INTG
INTG
186.2% more per $
INTG
8.8%
-177.4%
LAB
More free cash flow
INTG
INTG
$22.6M more FCF
INTG
$-481.0K
$-23.1M
LAB
Faster 2-yr revenue CAGR
INTG
INTG
Annualised
INTG
7.8%
-12.2%
LAB

Income Statement — Q2 FY2026 vs Q3 FY2025

Metric
INTG
INTG
LAB
LAB
Revenue
$17.3M
$19.6M
Net Profit
$1.5M
$-34.7M
Gross Margin
48.5%
Operating Margin
11.6%
-168.5%
Net Margin
8.8%
-177.4%
Revenue YoY
19.8%
-11.5%
Net Profit YoY
155.6%
-28.8%
EPS (diluted)
$0.71
$-0.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
INTG
INTG
LAB
LAB
Q4 25
$17.3M
Q3 25
$17.9M
$19.6M
Q2 25
$16.2M
$21.8M
Q1 25
$16.8M
$40.8M
Q4 24
$14.4M
Q3 24
$16.9M
$22.1M
Q2 24
$13.4M
$22.5M
Q1 24
$14.9M
$45.5M
Net Profit
INTG
INTG
LAB
LAB
Q4 25
$1.5M
Q3 25
$-535.0K
$-34.7M
Q2 25
$-2.2M
$-33.5M
Q1 25
$-578.0K
$-26.0M
Q4 24
$-2.7M
Q3 24
$-398.0K
$-26.9M
Q2 24
$-4.9M
$-45.7M
Q1 24
$-3.2M
$-32.2M
Gross Margin
INTG
INTG
LAB
LAB
Q4 25
Q3 25
48.5%
Q2 25
48.8%
Q1 25
48.4%
Q4 24
Q3 24
54.9%
Q2 24
46.1%
Q1 24
53.1%
Operating Margin
INTG
INTG
LAB
LAB
Q4 25
11.6%
Q3 25
15.3%
-168.5%
Q2 25
8.1%
-118.1%
Q1 25
14.0%
-80.8%
Q4 24
5.9%
Q3 24
18.5%
-120.9%
Q2 24
3.7%
-134.5%
Q1 24
4.8%
-132.2%
Net Margin
INTG
INTG
LAB
LAB
Q4 25
8.8%
Q3 25
-3.0%
-177.4%
Q2 25
-13.9%
-153.7%
Q1 25
-3.4%
-63.8%
Q4 24
-18.9%
Q3 24
-2.4%
-122.0%
Q2 24
-36.7%
-203.3%
Q1 24
-21.3%
-70.6%
EPS (diluted)
INTG
INTG
LAB
LAB
Q4 25
$0.71
Q3 25
$-0.25
$-0.09
Q2 25
$-0.09
Q1 25
$-0.27
$-0.07
Q4 24
$-1.26
Q3 24
$-0.18
$-0.07
Q2 24
$-0.12
Q1 24
$-1.44
$-0.27

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
INTG
INTG
LAB
LAB
Cash + ST InvestmentsLiquidity on hand
$7.5M
$129.4M
Total DebtLower is stronger
$233.2M
Stockholders' EquityBook value
$-85.2M
$399.7M
Total Assets
$101.1M
$539.6M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
INTG
INTG
LAB
LAB
Q4 25
$7.5M
Q3 25
$6.0M
$129.4M
Q2 25
$6.1M
$158.6M
Q1 25
$4.8M
$150.9M
Q4 24
$15.4M
Q3 24
$12.2M
$210.6M
Q2 24
$11.6M
$269.8M
Q1 24
$19.5M
$287.1M
Total Debt
INTG
INTG
LAB
LAB
Q4 25
$233.2M
Q3 25
$237.8M
Q2 25
$240.5M
Q1 25
$241.5M
Q4 24
$227.2M
Q3 24
$218.1M
$55.2M
Q2 24
$225.7M
$55.1M
Q1 24
$225.0M
$55.0M
Stockholders' Equity
INTG
INTG
LAB
LAB
Q4 25
$-85.2M
Q3 25
$-86.7M
$399.7M
Q2 25
$-86.1M
$424.5M
Q1 25
$-84.5M
$454.6M
Q4 24
$-83.9M
Q3 24
$-80.9M
$489.3M
Q2 24
$-80.3M
$510.3M
Q1 24
$-76.4M
$577.3M
Total Assets
INTG
INTG
LAB
LAB
Q4 25
$101.1M
Q3 25
$102.5M
$539.6M
Q2 25
$104.1M
$557.0M
Q1 25
$103.2M
$579.6M
Q4 24
$110.6M
Q3 24
$109.3M
$681.5M
Q2 24
$107.8M
$708.7M
Q1 24
$119.0M
$777.7M
Debt / Equity
INTG
INTG
LAB
LAB
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.11×
Q2 24
0.11×
Q1 24
0.10×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
INTG
INTG
LAB
LAB
Operating Cash FlowLast quarter
$-23.0K
$-22.2M
Free Cash FlowOCF − Capex
$-481.0K
$-23.1M
FCF MarginFCF / Revenue
-2.8%
-118.1%
Capex IntensityCapex / Revenue
2.6%
4.5%
Cash ConversionOCF / Net Profit
-0.02×
TTM Free Cash FlowTrailing 4 quarters
$739.0K
$-111.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
INTG
INTG
LAB
LAB
Q4 25
$-23.0K
Q3 25
$-296.0K
$-22.2M
Q2 25
$5.9M
$-20.7M
Q1 25
$-854.0K
$-30.3M
Q4 24
$-781.0K
Q3 24
$3.4M
$-27.9M
Q2 24
$6.8M
$-39.0M
Q1 24
$1.9M
$-62.5M
Free Cash Flow
INTG
INTG
LAB
LAB
Q4 25
$-481.0K
Q3 25
$-1.3M
$-23.1M
Q2 25
$3.6M
$-22.6M
Q1 25
$-1.2M
$-35.3M
Q4 24
$-1.1M
Q3 24
$3.1M
$-30.1M
Q2 24
$2.7M
$-41.0M
Q1 24
$1.1M
$-63.3M
FCF Margin
INTG
INTG
LAB
LAB
Q4 25
-2.8%
Q3 25
-7.1%
-118.1%
Q2 25
22.5%
-103.6%
Q1 25
-6.8%
-86.6%
Q4 24
-7.8%
Q3 24
18.3%
-136.4%
Q2 24
20.4%
-182.2%
Q1 24
7.6%
-138.9%
Capex Intensity
INTG
INTG
LAB
LAB
Q4 25
2.6%
Q3 25
5.4%
4.5%
Q2 25
13.9%
8.7%
Q1 25
1.8%
12.4%
Q4 24
2.4%
Q3 24
1.6%
10.2%
Q2 24
30.4%
8.6%
Q1 24
4.9%
1.7%
Cash Conversion
INTG
INTG
LAB
LAB
Q4 25
-0.02×
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

INTG
INTG

Hotel Operations$12.7M73%
Real Estate Operation$4.6M27%

LAB
LAB

Consumables$8.7M45%
Services And Other Revenue$5.8M29%
Instruments$5.1M26%

Related Comparisons